Apertura Gene Therapy has entered several licensing agreements to advance CNS treatments using its TfR1 CapX technology.

Amphastar has signed an exclusive license agreement with Anji for the development, production, use and commercialisation of 3 ...

PureTech's latest spinoff Celea Therapeutics was created to progress the former's lead respiratory IPF programme, ...

Insmed’s drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is ...

PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates ...

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical ...

Our editorial team dives into the pharma industry's reaction to US tariffs on imports from the European Union and major trends from Q2 earnings calls.

Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.